dapagliflozin,empagliflozin
astrazeneca,eli lilly,Boehringer Ingelheim
[]
#esccongress | deliver and emperor-preserved
this meta-analysis of the two large dedicated outcomes trials of sglt2i in hf with mildly reduced or preserved ejection fraction confirms that the sglt2i reduced cv death or hospitalisation for hf. 
Latest research in cardiology | Breaking news, insights, interviews, live tweeting and updates from major conferences. Co-published by @ilpensiero | @think2it